Korro Bio, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $12.44
- 52-Week Range
- $5.20 – $17.35
- Market Cap
- $167.32M
- P/E (TTM)
- —
- EPS (TTM)
- -8.89
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.89
- PEG Ratio
- —
- Return on Equity
- -113.26%
- Return on Assets
- -30.73%
- Gross Margin
- 0.00%
- Operating Margin
- -5891.49%
- Profit Margin
- 0.00%
- Current Ratio
- 7.30
- Debt/Equity
- 0.47
- Total Debt
- $41.52M
- Free Cash Flow
- $-34.05M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $107.28M
Market Snapshot
About
Korro Bio is a biopharmaceutical company pioneering RNA editing therapeutics using proprietary OPERA (Oligonucleotide Promoted Editing of RNA) technology. The company's platform enables precise, programmable editing of RNA to correct disease-causing mutations and modulate protein function. Korro is developing treatments for genetic diseases affecting the liver, central nervous system, and other organs with high unmet medical needs.